Similar articles

• Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing's Disease.

  Araki T, Wang J, Lawrence R, Kawakami Y. Araki T, et al. Endocrinology. 2022 Aug 1;163(8):bqac086. doi: 10.1210/endocr/bqac086. Endocrinology. 2022. PMID: 35678423 Free PMC article.
• Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.

  Liu NA, Araki T, Cuevas-Ramos D, Hong J, Ben-Shlomo A, Tone Y, Tone M, Melmed S. Liu NA, et al. J Clin Endocrinol Metab. 2015 Jul;100(7):2557-64. doi: 10.1210/jc.2015-1606. Epub 2015 May 5. J Clin Endocrinol Metab. 2015. PMID: 25942479 Free PMC article.
• E2F1-mediated human POMC expression in ectopic Cushing's syndrome.

  Araki T, Liu NA, Tone Y, Cuevas-Ramos D, Heltsley R, Tone M, Melmed S. Araki T, et al. Endocr Relat Cancer. 2016 Nov;23(11):857-870. doi: 10.1530/ERC-16-0206. Epub 2016 Oct 7. Endocr Relat Cancer. 2016. PMID: 27935805 Free PMC article.
• Somatostatin and somatostatin receptors in Cushing's disease.

  Hofland LJ. Hofland LJ. Mol Cell Endocrinol. 2008 May 14;286(1-2):199-205. doi: 10.1016/j.mce.2007.10.015. Epub 2007 Nov 22. Mol Cell Endocrinol. 2008. PMID: 18221833 Review.
• PPAR-gamma in Cushing's disease.

  Heaney AP. Heaney AP. Pituitary. 2004;7(4):265-9. doi: 10.1007/s11102-005-1430-8. Pituitary. 2004. PMID: 16416039 Review.